Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis

Completed · Phase 3

Conditions studied: Allergic Conjunctivitis

In brief

The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allergic conjunctivitis

Key facts

Study ID

NCT00241319

Run by

Vistakon Pharmaceuticals

People needed

150

Starts

2005-10-01

Last updated by the study team

2011-09-27

Who can join

Age: 10 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• history of ocular allergies and a positive skin test reaction to cat hair,
• cat dander, grasses, ragweed, and/or trees within the past 24 months;
• calculated best-corrected visual acuity of 0.6 logMar or better in each eye; - positive bilateral conjunctival allergy challenge reaction

You may not qualify if…

• narrow angle glaucoma,
• clinically significant blepharitis, follicular conjunctivitis, iritis
• pterygium or diagnosis of dry eye
• ocular surgical intervention within 3 months
• history of refractive surgery within 6 months
• known history of retinal detachment, diabetic retinopathy, or progressive retinal disease
• presence of active ocular infection positive history of an ocular herpetic infection
• preauricular lymphadenopath manifest signs or symptoms of clinically active allergic conjunctivitis

Where it is running

• Study site — Indianapolis, Indiana, United States
• Study site — Lewiston, Maine, United States
• Study site — Rochester, New York, United States
• Study site — Charlotte, North Carolina, United States
• Study site — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.